GlassScriptPhysician profile
Stacy Schonberg
NPI 1699061119
$3,035.09
in general payments reported to CMS, 2019-2025
27 companies · $793 in 2025
The $793 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $252 · 2021: $115 · 2022: $181 · 2023: $333 · 2024: $883 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $374.57 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $345.06 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $317.66 | 2019-2025 | Tryptyr, Eysuvis, Rocklatan |
| Abbvie INC. | $300.70 | 2022-2025 | Lumigan, Alphagan P |
| Novartis Pharmaceuticals Corporation | $248.70 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $231.02 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $224.10 | 2019-2025 | Cequa |
| Glaukos Corporation | $190.08 | 2023-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Allergan, INC. | $136.52 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $124.34 | 2019 | |
| Shire North American Group INC | $76.56 | 2019 | |
| Amgen INC. | $76.29 | 2024-2025 | Tepezza |
| Alimera Sciences, INC. | $58.50 | 2019 | |
| Dompe US, INC. | $45.20 | 2024-2025 | Oxervate |
| Harrow Eye, LLC | $37.97 | 2024 | Vevye |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $37.87 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.72 | 2019 | |
| Kala Pharmaceuticals, INC. | $23.65 | 2022 | |
| Biotissue Holdings INC. | $23.28 | 2023 | |
| Genmab U.S., INC. | $22.60 | 2024 | Tivdak |
| Horizon Therapeutics Plc | $21.13 | 2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $19.64 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $18.76 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.43 | 2024 | Acthar |
| Visioneering Technologies, INC. | $15.33 | 2019 | |
| Eyepoint US, INC. | $15.18 | 2022 | |
| Synergeyes, INC. | $9.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Schonberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.